Clinical Laserthermia Systems to host Strategy Update Event on February 15
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) invites investors, anlysts and media to attend a Strategy Update Event on February 15, 2023 at 13.00-15.00 CET.
The Strategy Update is a hybrid event. Participants are welcome to participate either physically, at the Redeye office, Mäster Samuelsgatan 42, 10th floor, Stockholm, Sweden, or digitally.
Dan J. Mogren, CEO of CLS, and members from the management team will present the company´s strategic priorities and its commercial roll-out. The presentations will be held in English.
Following the presentations, there will be a Q&A session moderated by Redeye analyst Gustaf Meyer. Viewers will have the opportunity to ask questions via the webcast chat or send questions beforehand to info@clinicallaser.se.
Registrate to participate physically here: https://bit.ly/408qGSF. No pre-registration is required to watch the webcast.
Follow the event via webcast here: https://www.redeye.se/events/872234/strategy-update-cls
Webcast recoding will be available after the event on clinicallaser.se.
The information was submitted for publication, through the agency of the contact person set out below on 8 February 2023.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: clinicallaser.se